On May 16th, Johnson&Johnson announced that they had reached a final agreement with Proteology to acquire biotechnology company Proteology for $850 million in cash. The transaction is expected to be completed by mid-2024, depending on antitrust review and other customary transaction conditions. Johnson&Johnson stated that this acquisition will strengthen the company's dermatology product portfolio and have the opportunity to meet the high demand in the field of atopic dermatitis (AD).